The Rho Associated Protein Kinase 2 pipeline drugs market research report outlays comprehensive information on the Rho Associated Protein Kinase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Rho Associated Protein Kinase 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Respiratory, Non Malignant Disorders, Gastrointestinal, and Oncology which include the indications Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), Metabolic Dysfunction-Associated Steatohepatitis (MASH), Crohn’s Disease (Regional Enteritis), Pancreatic Cancer, and Pancreatic Ductal Adenocarcinoma. It also reviews key players involved in Rho Associated Protein Kinase 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Rho Associated Protein Kinase 2 pipeline targets constitutes close to 19 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 1, 4, 1, 1, and 10 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 1, and 1 molecule.
Rho Associated Protein Kinase 2 overview
Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.
For a complete picture of Rho Associated Protein Kinase 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.